Zeke Capital Advisors LLC Trims Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Zeke Capital Advisors LLC reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.8% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 5,007 shares of the medical research company’s stock after selling 307 shares during the period. Zeke Capital Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,470,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Private Trust Co. NA raised its stake in Thermo Fisher Scientific by 66.7% during the 2nd quarter. Private Trust Co. NA now owns 3,273 shares of the medical research company’s stock valued at $961,000 after acquiring an additional 1,310 shares during the last quarter. Parallel Advisors LLC raised its stake in Thermo Fisher Scientific by 4.4% during the 1st quarter. Parallel Advisors LLC now owns 9,416 shares of the medical research company’s stock valued at $2,578,000 after acquiring an additional 393 shares during the last quarter. Barrett Asset Management LLC raised its stake in Thermo Fisher Scientific by 0.4% during the 1st quarter. Barrett Asset Management LLC now owns 111,500 shares of the medical research company’s stock valued at $30,520,000 after acquiring an additional 395 shares during the last quarter. CX Institutional purchased a new stake in Thermo Fisher Scientific during the 1st quarter valued at approximately $36,000. Finally, Gateway Investment Advisers LLC raised its stake in Thermo Fisher Scientific by 45.5% during the 2nd quarter. Gateway Investment Advisers LLC now owns 38,146 shares of the medical research company’s stock valued at $11,203,000 after acquiring an additional 11,928 shares during the last quarter. 88.02% of the stock is owned by institutional investors and hedge funds.

TMO has been the subject of several analyst reports. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $299.00 price objective for the company in a research note on Wednesday, June 12th. Needham & Company LLC upped their price objective on Thermo Fisher Scientific from $315.00 to $321.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. BTIG Research upped their price objective on Thermo Fisher Scientific to $320.00 and gave the company a “buy” rating in a research note on Thursday, May 23rd. Argus upped their price objective on Thermo Fisher Scientific from $285.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. Finally, UBS Group boosted their target price on Thermo Fisher Scientific from $305.00 to $320.00 and gave the stock a “buy” rating in a research report on Thursday, May 23rd. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $303.17.

NYSE TMO traded down $4.64 on Monday, hitting $270.18. 803,883 shares of the company’s stock were exchanged, compared to its average volume of 1,393,107. The company has a current ratio of 1.49, a quick ratio of 1.07 and a debt-to-equity ratio of 0.58. The firm has a 50-day moving average price of $291.36. Thermo Fisher Scientific Inc. has a fifty-two week low of $208.34 and a fifty-two week high of $305.45. The stock has a market cap of $109.92 billion, a price-to-earnings ratio of 24.30, a price-to-earnings-growth ratio of 1.80 and a beta of 1.11.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.04 earnings per share for the quarter, topping analysts’ consensus estimates of $3.01 by $0.03. The business had revenue of $6.32 billion for the quarter, compared to analysts’ expectations of $6.31 billion. Thermo Fisher Scientific had a return on equity of 17.11% and a net margin of 14.24%. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.75 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 12.23 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Tuesday, September 17th will be issued a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.28%. The ex-dividend date of this dividend is Monday, September 16th. Thermo Fisher Scientific’s dividend payout ratio is currently 6.83%.

In related news, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 30th. The stock was sold at an average price of $284.83, for a total value of $14,241,500.00. Following the sale, the chief executive officer now owns 342,193 shares in the company, valued at approximately $97,466,832.19. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Stephen Williamson sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $268.29, for a total value of $670,725.00. Following the completion of the sale, the chief financial officer now owns 40,029 shares in the company, valued at approximately $10,739,380.41. The disclosure for this sale can be found here. In the last 90 days, insiders sold 52,775 shares of company stock worth $14,986,676. Insiders own 0.45% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

See Also: Insider Trading – What You Need to Know

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.